Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Legacy HealthcareLegacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical DrugsThe "ADVANCING BOTANICAL DRUG DEVELOPMENT ACT OF 2026," introduced on Aug 27, 2026, would provide 12-year post-approval market exclusivity to encourage investment in FDA-regulated botanical drugs innovation EPALINGES, Switzerland, Sept. 3, 2026 -- Legacy Healthcare welcomes...
- Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth ConferenceProfound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.
- SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense CompanySRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today is providing shareholders with an update on its portfolio company ARMR Sciences (“ARMR”), a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl, from its CEO, Collin Gage.
- Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)Clinical outcomes from 264 PH-LHD patients demonstrate a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and sustained concurrent improvements in functional capacity, supporting the multi-dimensional therapeutic benefits of the Pulmonary...
- CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference60 Degrees Pharma (Nasdaq: SXTP) will present on demand at H.C. Wainwright beginning Sept. 11 and hold 1 x 1 investor meetings Sept. 14–16 in New York.
- Northway BiotechFIRST IN THE BALTICS: NORTHWAY BIOTECH OPENS €61 MILLION CELL THERAPY AND PERSONALIZED MEDICINE CDMO IN VILNIUSBuilding on more than 22 years of CDMO experience across biologics and advanced therapies, Northway Biotech is significantly expanding its development and manufacturing capacity with a new 3,500 sq. m facility featuring up to 20 independent cGMP manufacturing lines and first customer...
- Quince Therapeutics, Inc.Quince Therapeutics to Participate in September 2026 Investor ConferencesQuince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026:
- Krystal Biotech, Inc.Krystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceKrystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.
- ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT AUGUST 2026Zinzino group revenue increased with a total of 15 %, compared with the previous year. — The revenue in August for Zinzino's sales markets increased by 16 % and amounted to SEK 280.9 (242.5) million. Faun Pharma's external sales amounted to...
- Commure Ambient AI Achieves Class I Certification and MHRA RegistrationCommure Ambient AI is now available across the UK and Europe as CE-marked Class I medical device software, registered with the MHRA.
- ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord InjuryEINDHOVEN, the Netherlands, Sept. 03, 2026 -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, today announces the first implant in the EIGER clinical feasibility study evaluating the investigational ARC-IM® System for restoring mobility in people with subacute or chronic spinal cord injury (SCI).